The specter of generic rivalry has consistently loomed around copyright’s iconic drug, PDE5 Inhibitor, raising questions about the prospects of similar drug ventures. While first times saw impressive returns, the intellectual property expiration has allowed the way for discounted alternatives, likely diminishing revenue and posing a real risk for